Blocking Fis1 Restores Bone Formation After Radiation Therapy
Radiation triggers a Ca²⁺-NFATc1-Fis1 cascade that fragments mitochondria in bone marrow stem cells, halting bone repair — and silencing Fis1 reverses it.
Summary
Radiation therapy for head and neck cancers frequently causes osteoradionecrosis, a serious bone-loss complication. This study identifies a key molecular culprit: the mitochondrial fission protein Fis1. Radiation elevates intracellular calcium, which activates calcineurin and the transcription factor NFATc1, driving Fis1 overexpression. Excess Fis1 fragments mitochondria in mesenchymal stem cells, crippling their energy production and antioxidant capacity, and pushing them toward fat-cell rather than bone-cell differentiation. In irradiated mice, silencing Fis1 via intra-bone-marrow siRNA injection significantly preserved bone volume, trabecular number, and bone mineral density while restoring osteogenic markers. The findings point to Fis1 inhibition as a promising therapeutic strategy for radiation-induced bone injury.
Detailed Summary
Osteoradionecrosis affects 3–8% of patients receiving radiotherapy for head and neck cancers, causing avascular bone necrosis, impaired healing, and infection risk. Current treatments — surgery, antibiotics, hyperbaric oxygen — yield inconsistent results, underscoring the need to understand the cellular mechanisms driving this complication. This study from Sun Yat-sen University and the National University of Singapore provides a detailed mechanistic account of how radiation derails bone marrow mesenchymal stem cell (MSC) function through mitochondrial disruption.
Using 8-week-old male C57BL/6J mice exposed to a single 8 Gy X-ray dose to bilateral tibiae, the researchers established an in vivo radiation-induced bone injury model. A parallel in vitro system used primary bone marrow MSCs irradiated at 8 Gy and then cultured in osteogenic medium for up to 21 days. Mitochondrial morphology was assessed by transmission electron microscopy (TEM) and MitoTracker staining; function was measured via Seahorse XF96 respirometry, ATP luminescence assays, and mitochondrial membrane potential (TMRE staining). Osteogenesis was evaluated by ALP activity, Alizarin Red S calcium deposition, and qPCR for Runx2, Alp, and Ocn.
Radiation dramatically increased expression of Fis1, a mitochondrial outer-membrane receptor that recruits the fission GTPase Drp1. This drove excessive mitochondrial fragmentation — mitochondria shifted from elongated, rod-shaped networks to small, spherical puncta (aspect ratio approaching 1.0). Functionally, irradiated MSCs showed significantly reduced basal and maximal oxygen consumption rates, lower ATP production, diminished mitochondrial membrane potential, elevated reactive oxygen species (ROS), and reduced superoxide dismutase (SOD) activity. These bioenergetic deficits correlated with suppressed osteogenic differentiation and enhanced adipogenic differentiation, mirroring the clinical shift toward bone marrow fat accumulation seen in osteoradionecrosis.
Mechanistically, the study traced Fis1 upregulation upstream to a calcium-calcineurin-NFATc1 signaling axis. Radiation increased intracellular Ca²⁺ influx, which activated the phosphatase calcineurin (CaN), promoting dephosphorylation and nuclear translocation of NFATc1. Chromatin immunoprecipitation and reporter assays confirmed that nuclear NFATc1 directly binds the Fis1 promoter to drive transcription. Knockdown of NFATc1 by siRNA blocked Fis1 upregulation and partially rescued mitochondrial morphology and osteogenic capacity. Conversely, NFATc1 overexpression via lentiviral transduction recapitulated the radiation phenotype even without irradiation.
Critically, in vivo Fis1 silencing via intra-bone-marrow siRNA injection (4 injections of 3 nmol/20 g body mass, beginning one day before irradiation) significantly attenuated bone loss at 28 days post-radiation. Micro-CT analysis showed that Fis1 knockdown preserved bone volume/total volume (BV/TV), trabecular number (Tb.N), and bone mineral density (BMD) compared to irradiated controls. Histological and immunohistochemical analyses confirmed increased osteocalcin (OCN) staining, reduced TRAP-positive osteoclasts, and decreased PPAR-γ (adipogenic marker) in the Fis1-silenced group. These results establish Fis1 as a druggable node in radiation-induced bone injury and suggest that pharmacological or genetic inhibition of Fis1 — or upstream Ca²⁺/CaN/NFATc1 signaling — could complement or replace current osteoradionecrosis management strategies.
Key Findings
- Radiation (8 Gy) significantly upregulated Fis1 expression in murine bone marrow MSCs both in vivo and in vitro, driving mitochondrial fragmentation as measured by TEM aspect-ratio analysis
- Irradiated MSCs showed markedly reduced basal and maximal oxygen consumption rates (OCR) and ATP production compared to non-irradiated controls, indicating impaired oxidative phosphorylation
- ROS levels were significantly elevated and SOD antioxidant activity significantly reduced in irradiated MSCs, reflecting collapsed mitochondrial redox defense
- NFATc1 knockdown blocked radiation-induced Fis1 upregulation and partially restored mitochondrial morphology and osteogenic differentiation; NFATc1 overexpression alone recapitulated the radiation phenotype
- In vivo Fis1 siRNA treatment (4 intra-bone-marrow injections) significantly preserved BV/TV, Tb.N, and BMD at 28 days post-irradiation versus irradiated controls
- Fis1 silencing increased osteocalcin (OCN) immunostaining and reduced PPAR-γ and TRAP-positive cell counts in irradiated tibiae, indicating restored osteogenesis and reduced adipogenesis/osteoclast activity
- Calcium chelation and calcineurin inhibition upstream of NFATc1 each attenuated Fis1 transcription, confirming the Ca²⁺-CaN-NFATc1-Fis1 pathway as the mechanistic cascade
Methodology
The study used 8-week-old male C57BL/6J mice (n=6 per group: Control, IR, IR-siFis1) exposed to a single 8 Gy tibial X-ray dose, with intra-bone-marrow siRNA injections administered on 4 occasions. In vitro experiments used primary bone marrow MSCs irradiated at 8 Gy and assessed over 21 days in osteogenic medium. Mitochondrial function was quantified by Seahorse XF96 respirometry, ATP luminescence, TMRE membrane potential, and TEM morphometry; osteogenesis by ALP, Alizarin Red S, and qPCR. Statistical comparisons used standard group analyses; specific p-values and effect sizes are reported in figures but not uniformly stated in the text excerpt.
Study Limitations
The study used only male mice, limiting generalizability to female patients who represent a significant proportion of head and neck cancer survivors. The in vivo siRNA delivery was local (intra-bone-marrow injection), which may not reflect systemic therapeutic approaches, and the 28-day observation window may be insufficient to assess long-term bone remodeling outcomes. The authors do not explicitly declare conflicts of interest in the available text, and the study is preclinical, requiring validation in larger animal models and human MSC systems before clinical translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.